Lyell Immunopharma, Inc.LYELNASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank17
Studio
Year-over-Year Change

Year-over-year operating income growth rate

Percentile
P17
Within normal range
vs 3Y Ago
-0.9x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
PeriodValue
Q4 2025-66.47%
Q3 202520.97%
Q2 202517.83%
Q1 202571.48%
Q4 2024-298.27%
Q3 20241.99%
Q2 20247.28%
Q1 20247.11%
Q4 20231.23%
Q3 20238.03%
Q2 2023-2.20%
Q1 2023-302.98%
Q4 202276.02%
Q3 2022-80.08%
Q2 202247.62%
Q1 2022-46.26%
Q4 20211.68%
Q3 202121.60%
Q2 2021-36.47%
Q1 2021-16.25%
Q4 2020-7.28%
Q3 202064.08%
Q2 2020-210.77%
Q1 20200.00%